UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

According to UCB, bimekizumab met its co-primary endpoints at week 16 of the study, demonstrating superiority over Humira in achieving a 90% improvement in the psoriasis area, severity index and

Envision Pharma Group announces changes in its executive team

Brian Hepburn (left), Envision Pharma Group executive co-chair, and David Thompson, chief executive officer (right). ... The move coincides with the appointment of current CEO Brian Hepburn to the new position of executive co-chair of the group.

Mylan, Biocon’s Herceptin biosimilar launched in US

MSD – known as Merck &Co in North America – was the  first to launch a biosimilar of Herceptin in the EU, under the Ontruzant brand name.

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) – already dominating NSCLC therapy – is already approved for third-line SCLC treatment and is in a first-line phase 3 trial

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]